Galcanezumab News
Galcanezumab currently has 0 news articles, with 20 predicted indications.
This page combines the AI-predicted indications for Galcanezumab with the latest health news. Indications highlighted in orange have recent news coverage.
Drug Information
- Original indication: Emgality is indicated for the prophylaxis of migraine in adults who have at least 4 migraine days per month.
- Evidence level: L5
- Predicted indications (20):
- heparin cofactor 2 deficiency (99.5%)
- antithrombin deficiency type 2 (99.4%)
- factor 5 excess with spontaneous thrombosis (99.4%)
- thrombophilia (99.0%)
- migraine with brainstem aura (98.3%)
- migraine disorder (98.1%)
- atrophoderma vermiculata (91.5%)
- ulerythema ophryogenesis (90.3%)
- migraine with or without aura, susceptibility to (89.4%)
- hemorrhagic disease of newborn (81.3%)
- prekallikrein deficiency (72.2%)
- thrombotic disorder due to a platelet anomaly (70.7%)
- hypervitaminosis (70.3%)
- sciatic neuropathy (70.2%)
- obesity disorder (68.9%)
- monogenic obesity (68.6%)
- obsolete hypertelorism (disease) (66.7%)
- frontorhiny (63.8%)
- thrombophilia due to protein S deficiency, autosomal recessive (62.9%)
- thrombomodulin-related bleeding disorder (62.8%)
Related News (0)
No related news yet. When news mentions this drug, it will be collected and shown here automatically.
Disclaimer: The news on this page is collected automatically and is for research reference only; it does not constitute medical advice.